Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Renal Dysfunction in Acute Heart Failure

  • Han, Seong-Woo (Cardiovascular Center, Korea University, Guro Hospital) ;
  • Ryu, Kyu-Hyung (Department of Cardiovascular Medicine, Konkuk University Medical Center)
  • Published : 2011.10.30
⟨ Previous Next ⟩

Abstract

During treatment of acute heart failure (AHF), worsening renal function is often complicated and results in a complex clinical course. Furthermore, renal dysfunction is a strong independent predictor of long-term adverse outcomes in patients with AHF. Traditionally, the predominant cause of renal dysfunction has been attributed to impairment of cardiac output and relative underfilling of arterial perfusion. Recently, emerging data have led to the importance of venous congestion and elevated intra-abdominal pressure rather than confining it to impaired forward cardiac output as the primary driver of renal impairment. Relief of congestion is a major objective of AHF treatment but therapy is still based on the administration of loop diuretics. The results of the recently performed controlled studies for the assessment of new treatments to overcome resist-ance to diuretic treatment to protect kidneys from untoward effects have been mostly neutral. Better treatment of congestion in heart failure remains a major problem.

Keywords

References

  1. Adams KF Jr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149:209-16. https://doi.org/10.1016/j.ahj.2004.08.005
  2. Cleland JG, Swedberg K, Cohen-Solal A, et al. The Euro Heart Failure Survey of the EUROHEART survey programme: a survey on the quality of care among patients with heart failure in Europe: the Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology: the Medicines Evaluation Group Centre for Health Economics University of York. Eur J Heart Fail 2000;2:123-32.
  3. Zannad F, Mebazaa A, Juilliere Y, et al. Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: the EFICA Study. Eur J Heart Fail 2006; 8:697-705. https://doi.org/10.1016/j.ejheart.2006.01.001
  4. Fonarow GC, Abraham WT, Albert NM, et al. Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF). Arch Intern Med 2007;167:1493-502. https://doi.org/10.1001/archinte.167.14.1493
  5. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol 2008;52:1527-39. https://doi.org/10.1016/j.jacc.2008.07.051
  6. Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 2002;8:136-41. https://doi.org/10.1054/jcaf.2002.125289
  7. Schrier RW. Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor? J Am Coll Cardiol 2006;47:1-8. https://doi.org/10.1016/j.jacc.2005.07.067
  8. Klein L, Massie BM, Leimberger JD, et al. Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for exacerbations of Chronic Heart Failure (OPTIME-CHF). Circ Heart Fail 2008;1:25-33. https://doi.org/10.1161/CIRCHEARTFAILURE.107.746933
  9. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the Internaitional Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009;53:e1-90. https://doi.org/10.1016/j.jacc.2008.11.013
  10. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology: developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-442. https://doi.org/10.1093/eurheartj/ehn309
  11. Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 2010;16:e1-194. https://doi.org/10.1016/j.cardfail.2010.04.004
  12. O'Meara E, Chong KS, Gardner RS, Jardine AG, Neilly JB, McDonagh TA. The modification of diet in renal disease (MDRD) equations provide valid estimations of glomerular filtration rates in patients with advanced heart failure. Eur J Heart Fail 2006;8:63-7. https://doi.org/10.1016/j.ejheart.2005.04.013
  13. Choi DJ, Han S, Jeon ES, et al. Characteristics, Outcomes and Predictors of Long-Term Mortality for Patients Hospitalized for Acute Heart Failure: A Report From the Korean Heart Failure Registry. Korean Circ J 2011;41:363-71. https://doi.org/10.4070/kcj.2011.41.7.363
  14. Nohria A, Hasselblad V, Stebbins A, et al. Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol 2008;51:1268-74. https://doi.org/10.1016/j.jacc.2007.08.072
  15. Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 2006;47:1987-96. https://doi.org/10.1016/j.jacc.2005.11.084
  16. Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004;43:61-7. https://doi.org/10.1016/j.jacc.2003.07.031
  17. Damman K, Navis G, Voors AA, et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail 2007;13:599-608. https://doi.org/10.1016/j.cardfail.2007.04.008
  18. Cowie MR, Komajda M, Murray-Thomas T, Underwood J, Ticho B; POSH Investigators. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). Eur Heart J 2006;27:1216-22. https://doi.org/10.1093/eurheartj/ehi859
  19. Metra M, Nodari S, Parrinello G, et al. Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. Eur J Heart Fail 2008;10:188-95. https://doi.org/10.1016/j.ejheart.2008.01.011
  20. Damman K, Navis G, Smilde TD, et al. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 2007;9:872-78. https://doi.org/10.1016/j.ejheart.2007.05.010
  21. McCullough PA, Ahmad A. Cardiorenal syndromes. World J Cardiol 2011;3:1-9. https://doi.org/10.4330/wjc.v3.i1.1
  22. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004;109:1004-9. https://doi.org/10.1161/01.CIR.0000116764.53225.A9
  23. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J; ADHERE Scientific Advisory Committee and Investigators. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 2007;13:422-30. https://doi.org/10.1016/j.cardfail.2007.03.011
  24. Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009;53:589-96. https://doi.org/10.1016/j.jacc.2008.05.068
  25. Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 2009;53:582-8. https://doi.org/10.1016/j.jacc.2008.08.080
  26. Drazner MH, Rame JE, Stevenson LW, Dries DL. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med 2001;345:574-81. https://doi.org/10.1056/NEJMoa010641
  27. Damman K, Voors AA, Hillege HL, et al. Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. Eur J Heart Fail 2010;12:974-82. https://doi.org/10.1093/eurjhf/hfq118
  28. Uthoff H, Breidthardt T, Klima T, et al. Central venous pressure and impaired renal function in patients with acute heart failure. Eur J Heart Fail 2011;13:432-9. https://doi.org/10.1093/eurjhf/hfq195
  29. Funaya H, Kitakaze M, Node K, Minamino T, Komamura K, Hori M. Plasma adenosine levels increase in patients with chronic heart failure. Circulation 1997;95:1363-5. https://doi.org/10.1161/01.CIR.95.6.1363
  30. Metra M, O'Connor CM, Davison BA, et al. Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. Eur Heart J 2011;32:1519-34. https://doi.org/10.1093/eurheartj/ehr042
  31. Blankstein R, Bakris GL. Renal hemodynamic changes in heart failure. Heart Fail Clin 2008;4:411-23. https://doi.org/10.1016/j.hfc.2008.03.006
  32. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724-9. https://doi.org/10.1161/01.CIR.82.5.1724
  33. Chen HH, Schrier RW. Pathophysiology of volume overload in acute heart failure syndromes. Am J Med 2006;119:12(Supple 1):S11-6.
  34. Masuo K, Lambert GW, Esler MD, Rakugi H, Ogihara T, Schlaich MP. The role of sympathetic nervous activity in renal injury and endstage renal disease. Hypertens Res 2010;33:521-8. https://doi.org/10.1038/hr.2010.35
  35. Schrier RW, Berl T, Anderson RJ. Osmotic and nonosmotic control of vasopressin release. Am J Physiol 1979;236:F321-32.
  36. Schrier RW, Berl T. Nonosmolar factors affecting renal water excretion (first of two parts). N Engl J Med 1975;292:81-8. https://doi.org/10.1056/NEJM197501092920207
  37. Schrier RW, Berl T. Nonosmolar factors affecting renal water excretion (second of two parts). N Engl J Med 1975;292:141-5. https://doi.org/10.1056/NEJM197501162920306
  38. Haase-Fielitz A, Bellomo R, Devarajan P, et al. Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery: a prospective cohort study. Crit Care Med 2009;37: 553-60. https://doi.org/10.1097/CCM.0b013e318195846e
  39. Bonventre JV, Vaidya VS, Schmouder R, Feig P, Dieterle F. Next-generation biomarkers for detecting kidney toxicity. Nat Biotechnol 2010; 28:436-40. https://doi.org/10.1038/nbt0510-436
  40. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function: measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473-83. https://doi.org/10.1056/NEJMra054415
  41. Waikar SS, Bonventre JV. Creatinine kinetics and the definition of acute kidney injury. J Am Soc Nephrol 2009;20:672-9. https://doi.org/10.1681/ASN.2008070669
  42. Filippatos G, Rossi J, Lloyd-Jones DM, et al. Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study. J Card Fail 2007;13:360-4. https://doi.org/10.1016/j.cardfail.2007.02.005
  43. Cauthen CA, Lipinski MJ, Abbate A, et al. Relation of blood urea nitrogen to long-term mortality in patients with heart failure. Am J Cardiol 2008;101:1643-7. https://doi.org/10.1016/j.amjcard.2008.01.047
  44. Aronson D, Mittleman MA, Burger AJ. Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure. Am J Med 2004;116:466-73. https://doi.org/10.1016/j.amjmed.2003.11.014
  45. Lindenfeld J, Schirier RW. Blood urea nitrogen: A marker for adverse effects of loop diuretics? J Am Coll Cardiol 2011;58:383-5. https://doi.org/10.1016/j.jacc.2011.01.054
  46. Testani JM, Cappola TP, Brensinger CM, Shannon RP, Kimmel SE. Interaction between loop diuretic-associated mortality and blood urea nitrogen concentration in chronic heart failure. J Am Coll Cardiol 2011;58:375-82. https://doi.org/10.1016/j.jacc.2011.01.052
  47. Schrier RW. Blood urea nitrogen and serum creatinine: not married in heart failure. Circ Heart Fail 2008;1:2-5. https://doi.org/10.1161/CIRCHEARTFAILURE.108.770834
  48. Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003;14:2534-43. https://doi.org/10.1097/01.ASN.0000088027.54400.C6
  49. Zappitelli M, Washburn KK, Arikan AA, et al. Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children: a prospective cohort study. Crit Care 2007;11: R84. https://doi.org/10.1186/cc6089
  50. Aghel A, Shrestha K, Mullens W, Borowski A, Tang WH. Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J Card Fail 2010;16:49-54. https://doi.org/10.1016/j.cardfail.2009.07.003
  51. Grubb A. Diagnostic value of analysis of cystatin C and protein HC in biological fluids. Clin Nephrol 1992;38(Suppl 1):S20-7.
  52. Herget-Rosenthal S, Trabold S, Pietruck F, Holtmann M, Philipp T, Kribben A. Cystatin C: efficacy as screening test for reduced glomerular filtration rate. Am J Nephrol 2000;20:97-102. https://doi.org/10.1159/000013564
  53. Lassus JP, Nieminen MS, Peuhkurinen K, et al. Markers of renal function and acute kidney injury in acute heart failure: definitions and impact on outcomes of the cardiorenal syndrome. Eur Heart J 2010; 31:2791-8. https://doi.org/10.1093/eurheartj/ehq293
  54. Ichimura T, Bonventre JV, Bailly V, et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 1998;273:4135-42. https://doi.org/10.1074/jbc.273.7.4135
  55. Damman K, van Veldhuisen DJ, Navis G, et al. Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart 2010;96:1297-302. https://doi.org/10.1136/hrt.2010.194878
  56. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011;364:797-805. https://doi.org/10.1056/NEJMoa1005419
  57. Sarraf M, Masoumi A, Schrier RW. Cardiorenal syndrome in acute decompensated heart failure. Clin J Am Soc Nephrol 2009;4:2013-26. https://doi.org/10.2215/CJN.03150509
  58. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure: activation of the neurohumoral axis. Ann Intern Med 1985;103:1-6. https://doi.org/10.7326/0003-4819-103-1-1
  59. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007;297:1319-31. https://doi.org/10.1001/jama.297.12.1319
  60. Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Renal Physiol 2006;290:F273-8. https://doi.org/10.1152/ajprenal.00195.2005
  61. Maskin CS, Ocken S, Chadwick B, LeJemtel TH. Comparative systemic and renal effects of dopamine and angiotensin-converting enzyme inhibition with enalaprilat in patients with heart failure. Circulation 1985;72:846-52. https://doi.org/10.1161/01.CIR.72.4.846
  62. Friedrich JO, Adhikari N, Herridge MS, Beyene J. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 2005;142:510-24. https://doi.org/10.7326/0003-4819-142-7-200504050-00010
  63. Giamouzis G, Butler J, Starling RC, et al. Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. J Card Fail 2010;16:922-30. https://doi.org/10.1016/j.cardfail.2010.07.246
  64. Leier CV, Heban PT, Huss P, Bush CA, Lewis RP. Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure. Circulation 1978;58(3 Pt 1):466-75. https://doi.org/10.1161/01.CIR.58.3.466
  65. Yilmaz MB, Yalta K, Yontar C, et al. Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovasc Drugs Ther 2007;21:431-5. https://doi.org/10.1007/s10557-007-6066-7
  66. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007;297:1883-91. https://doi.org/10.1001/jama.297.17.1883
  67. Den Uil CA, Lagrand WK, Spronk PE, et al. Low-dose nitroglycerin improves microcirculation in hospitalized patients with acute heart failure. Eur J Heart Fail 2009;11:386-90. https://doi.org/10.1093/eurjhf/hfp021
  68. Mullens W, Abrahams Z, Francis GS, et al. Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol 2008;52:200-7. https://doi.org/10.1016/j.jacc.2008.02.083
  69. Teichman SL, Unemori E, Dschietzig T, et al. Relaxin, a pleiotropic vasodilator for the treatment of heart failure. Heart Fail Rev 2009;14:321-9. https://doi.org/10.1007/s10741-008-9129-3
  70. O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011;365:32-43. https://doi.org/10.1056/NEJMoa1100171
  71. Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol 1992;70:479-87. https://doi.org/10.1016/0002-9149(92)91194-9
  72. Bourge RC, Tallaj JA. Ultrafiltration: a new approach toward mechanical diuresis in heart failure. J Am Coll Cardiol 2005;46:2052-3. https://doi.org/10.1016/j.jacc.2005.09.014
  73. Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007;49:675-83. https://doi.org/10.1016/j.jacc.2006.07.073

Cited by

  1. Is there still a role for low-dose dopamine use in acute heart failure? vol.20, pp.5, 2011, https://doi.org/10.1097/mcc.0000000000000133
  2. Systemic Infusion of Expanded CD133 + Cells and Expanded CD133 + Cell-Derived EVs for the Treatment of Ischemic Cardiomyopathy in a Rat Model of AMI vol.2019, pp.None, 2011, https://doi.org/10.1155/2019/4802578
  3. Pathophysiology of Cardiorenal Syndrome and Use of Diuretics and Ultrafiltration as Volume Control vol.51, pp.8, 2011, https://doi.org/10.4070/kcj.2021.0996
  4. Acute Decompensated Heart Failure and the Kidney: Physiological, Histological and Transcriptomic Responses to Development and Recovery vol.10, pp.18, 2011, https://doi.org/10.1161/jaha.121.021312